vs
EXACT SCIENCES CORP（EXAS）与Worthington Steel, Inc.（WS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Worthington Steel, Inc.的1.0倍（$878.4M vs $871.9M），Worthington Steel, Inc.净利率更高（2.2% vs -9.8%，领先11.9%），EXACT SCIENCES CORP同比增速更快（23.1% vs 18.0%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $74.6M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 3.9%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
沃辛顿钢铁是总部位于美国俄亥俄州哥伦布市的工业制造企业，下设消费品和建筑建材两大业务板块，主营各类压力容器的设计与生产，覆盖丙烷、氧气、氦气储罐，制冷剂及工业气瓶，露营与民用气瓶，以及用于存储、处理、加热、扩容和流量控制的供水系统罐体等产品。
EXAS vs WS — 直观对比
营收规模更大
EXAS
是对方的1.0倍
$871.9M
营收增速更快
EXAS
高出5.1%
18.0%
净利率更高
WS
高出11.9%
-9.8%
自由现金流更多
EXAS
多$45.8M
$74.6M
两年增速更快
EXAS
近两年复合增速
3.9%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $871.9M |
| 净利润 | $-86.0M | $18.8M |
| 毛利率 | 70.1% | 10.7% |
| 营业利润率 | -9.4% | 2.5% |
| 净利率 | -9.8% | 2.2% |
| 营收同比 | 23.1% | 18.0% |
| 净利润同比 | 90.1% | 46.9% |
| 每股收益（稀释后） | $-0.45 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASWS
| Q4 25 | $878.4M | $871.9M | ||
| Q3 25 | $850.7M | $872.9M | ||
| Q2 25 | $811.1M | $832.9M | ||
| Q1 25 | $706.8M | $687.4M | ||
| Q4 24 | $713.4M | $739.0M | ||
| Q3 24 | $708.7M | $834.0M | ||
| Q2 24 | $699.3M | — | ||
| Q1 24 | $637.5M | $805.8M |
净利润EXASWS
| Q4 25 | $-86.0M | $18.8M | ||
| Q3 25 | $-19.6M | $36.8M | ||
| Q2 25 | $-1.2M | $55.7M | ||
| Q1 25 | $-101.2M | $13.8M | ||
| Q4 24 | $-864.6M | $12.8M | ||
| Q3 24 | $-38.2M | $28.4M | ||
| Q2 24 | $-15.8M | — | ||
| Q1 24 | $-110.2M | $49.0M |
毛利率EXASWS
| Q4 25 | 70.1% | 10.7% | ||
| Q3 25 | 68.6% | 13.2% | ||
| Q2 25 | 69.3% | 15.2% | ||
| Q1 25 | 70.8% | 11.8% | ||
| Q4 24 | 69.0% | 10.8% | ||
| Q3 24 | 69.4% | 12.0% | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | 14.9% |
营业利润率EXASWS
| Q4 25 | -9.4% | 2.5% | ||
| Q3 25 | -3.0% | 5.5% | ||
| Q2 25 | -0.3% | 8.0% | ||
| Q1 25 | -13.6% | 2.7% | ||
| Q4 24 | -122.8% | 2.6% | ||
| Q3 24 | -5.6% | 5.2% | ||
| Q2 24 | -3.8% | — | ||
| Q1 24 | -16.7% | 8.2% |
净利率EXASWS
| Q4 25 | -9.8% | 2.2% | ||
| Q3 25 | -2.3% | 4.2% | ||
| Q2 25 | -0.1% | 6.7% | ||
| Q1 25 | -14.3% | 2.0% | ||
| Q4 24 | -121.2% | 1.7% | ||
| Q3 24 | -5.4% | 3.4% | ||
| Q2 24 | -2.3% | — | ||
| Q1 24 | -17.3% | 6.1% |
每股收益（稀释后）EXASWS
| Q4 25 | $-0.45 | $0.37 | ||
| Q3 25 | $-0.10 | $0.72 | ||
| Q2 25 | $-0.01 | $1.11 | ||
| Q1 25 | $-0.54 | $0.27 | ||
| Q4 24 | $-4.69 | $0.25 | ||
| Q3 24 | $-0.21 | $0.56 | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.60 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $89.8M |
| 总债务越低越好 | — | $72.1M |
| 股东权益账面价值 | $2.4B | $1.1B |
| 总资产 | $5.9B | $2.1B |
| 负债/权益比越低杠杆越低 | — | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资EXASWS
| Q4 25 | $964.7M | $89.8M | ||
| Q3 25 | $1.0B | $78.3M | ||
| Q2 25 | $858.4M | $38.0M | ||
| Q1 25 | $786.2M | $63.3M | ||
| Q4 24 | $1.0B | $52.0M | ||
| Q3 24 | $1.0B | $36.0M | ||
| Q2 24 | $946.8M | — | ||
| Q1 24 | $652.1M | $60.8M |
总债务EXASWS
| Q4 25 | — | $72.1M | ||
| Q3 25 | — | $73.4M | ||
| Q2 25 | — | $151.5M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $115.0M | ||
| Q3 24 | — | $122.2M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $147.2M |
股东权益EXASWS
| Q4 25 | $2.4B | $1.1B | ||
| Q3 25 | $2.5B | $1.1B | ||
| Q2 25 | $2.5B | $1.1B | ||
| Q1 25 | $2.4B | $1.0B | ||
| Q4 24 | $2.4B | $1.0B | ||
| Q3 24 | $3.2B | $1.0B | ||
| Q2 24 | $3.2B | — | ||
| Q1 24 | $3.1B | $937.6M |
总资产EXASWS
| Q4 25 | $5.9B | $2.1B | ||
| Q3 25 | $5.9B | $2.2B | ||
| Q2 25 | $5.8B | $2.0B | ||
| Q1 25 | $5.7B | $1.8B | ||
| Q4 24 | $5.9B | $1.7B | ||
| Q3 24 | $6.7B | $1.8B | ||
| Q2 24 | $6.7B | — | ||
| Q1 24 | $6.4B | $1.8B |
负债/权益比EXASWS
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.14× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $99.3M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $74.6M |
| 自由现金流率自由现金流/营收 | 13.7% | 8.6% |
| 资本支出强度资本支出/营收 | 3.6% | 2.8% |
| 现金转化率经营现金流/净利润 | — | 5.28× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $72.5M |
8季度趋势，按日历期对齐
经营现金流EXASWS
| Q4 25 | $151.7M | $99.3M | ||
| Q3 25 | $219.9M | $-6.3M | ||
| Q2 25 | $89.0M | $53.9M | ||
| Q1 25 | $30.8M | $53.8M | ||
| Q4 24 | $47.1M | $68.0M | ||
| Q3 24 | $138.7M | $54.6M | ||
| Q2 24 | $107.1M | — | ||
| Q1 24 | $-82.3M | $44.7M |
自由现金流EXASWS
| Q4 25 | $120.4M | $74.6M | ||
| Q3 25 | $190.0M | $-35.7M | ||
| Q2 25 | $46.7M | $8.4M | ||
| Q1 25 | $-365.0K | $25.2M | ||
| Q4 24 | $10.7M | $33.2M | ||
| Q3 24 | $112.6M | $33.1M | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | $22.3M |
自由现金流率EXASWS
| Q4 25 | 13.7% | 8.6% | ||
| Q3 25 | 22.3% | -4.1% | ||
| Q2 25 | 5.8% | 1.0% | ||
| Q1 25 | -0.1% | 3.7% | ||
| Q4 24 | 1.5% | 4.5% | ||
| Q3 24 | 15.9% | 4.0% | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | 2.8% |
资本支出强度EXASWS
| Q4 25 | 3.6% | 2.8% | ||
| Q3 25 | 3.5% | 3.4% | ||
| Q2 25 | 5.2% | 5.5% | ||
| Q1 25 | 4.4% | 4.2% | ||
| Q4 24 | 5.1% | 4.7% | ||
| Q3 24 | 3.7% | 2.6% | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 5.9% | 2.8% |
现金转化率EXASWS
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | -0.17× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | 3.90× | ||
| Q4 24 | — | 5.31× | ||
| Q3 24 | — | 1.92× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.91× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
WS
| Direct | $844.1M | 97% |
| Toll | $27.8M | 3% |
